0
PINSABCS 2023 - Complete program listing
Dr. Tarantino - DESTINY BREAST
Q2: What are the steps you take to optimally manage ILD for patients on T-DXd (The 5 S Rules)?
CLINICAL IMPACT Series
Insights & Innovations: Panel discussion on Patient-Reported Outcomes and AI in breast cancer
ESMO 2023 - Neoadjuvant immunotherapy improves responses in HR-positive early breast cancer
Dr. Tarantino - DESTINY BREAST
Q1: In which patient profiles would you consider standard of care T-DXd for in the 2L HER2+ mBC setting? And is there a patient profile you would not consider it?
CLINICAL IMPACT Series